- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00220727
Rapid Infusion Of Immune Globulin Intravenous (IGIV) In Patients With ITP
Randomized, Controlled, Open Study Investigating IGIV-C, 10% Given at Different Infusion Rates on Intravascular Hemolysis in Patients With Idiopathic (Immune) Thrombocytopenic Purpura (ITP)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a prospective, randomized, single-center, open, cross-over trial in patients with a confirmed diagnosis of Idiopathic Thrombocytopenia Purpura (ITP). ITP is defined as isolated thrombocytopenia in a patient with no other clinically apparent associated conditions or factors that are known to cause thrombocytopenia as defined by the ITP Practice Guidelines Committee of the American Society of Hematology.
Immune Globulin Intravenous (Human), 10% Caprylate/Chromatography Purified (IGIV-C) at a dose of 1.0 g/kg will be given on 2 occasions as a single daily infusion for platelet counts < 30,000 microliters (uL) or if clinically indicated, at maximum intervals of six weeks. Eligible patients will be randomized into one of two cross-over groups. Patients randomized to Group 1 will receive their first IGIV-C infusion at a rate of 0.08 mL/kg/min and their second infusion at a rate of 0.14 mL/kg/min. Conversely patients randomized to Group 2 will receive their first IGIV-C infusion at a rate of 0.14 mL/kg/min and their second infusion at a rate of 0.08 mL/kg/min according to the following schema:
Group 1:
- Infusion #1 (Week 0) IGIV-C (0.08 mL/kg/min)
- Infusion #2 (Week <6) IGIV-C (0.14 mL/kg/min)
Group 2:
- Infusion #1 (Week 0) IGIV-C (0.14 mL/kg/min)
- Infusion #2 (Week <6) IGIV-C (0.08 mL/kg/min)
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10021-4885
- New York Presbyterian Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Written informed consent from patient or legal guardian (according to institutional review board requirements)obtained prior to initiation of any study related procedures
- Male and female subjects age between 12 and 75 years
- Confirmed diagnosis of ITP logged in medical records available prior to entry into the trial.
- Patients must have a platelet count < 30 x Giga/L (this level can be higher if clinically indicated).
- Previously splenectomized patients may be included.
- Any previously conducted bone marrow aspirations if conducted following diagnosis of ITP must be consistent with the ITP diagnosis (increased or normal levels of megakaryocytes in otherwise normal bone marrow).
Exclusion Criteria:
- History of allergic or other clinically significant reaction to human gamma globulin or other plasma proteins and/or blood products.
- Female patient who is pregnant or lactating or is not on an adequate program of contraception if of child-bearing potential.
- Documented history of selective immunoglobulin A (IgA) deficiency (serum <5.0 mg/dL) and known antibodies to IgA.
- Currently on intermittent prednisone therapy. Prednisone therapy is allowed only if the patient has been on stable daily doses of prednisone for the preceding month and maintains the same treatment regimen throughout the study.
- Renal or liver impairment defined by creatinine > 2.5 mg/dL, or direct bilirubin >1.5 X the upper limit of normal or liver transaminases (AST or ALT) > 3 times the upper limit of normal.
- Received anti-D or IGIV infusions within the past 14 days
- Pre-treatment with the exception of acetominophen, routinely required to control/ameliorate IGIV infusion-related adverse events (AEs), or any patient who has been, unresponsive to IGIV therapy for their ITP
- History or clinical evidence of medical conditions felt to be the underlying cause of their thrombocytopenia. Such conditions commonly include systemic lupus erythematosus, history of chronic lymphocytic leukemia, dysplasia, agammaglobulinemia, treatment with heparin, quinidine, quinine, trimethoprim-sulfamethoxazole, or ticlopidine or any other drug thought to be the cause of patient's thrombocytopenia, congenital or hereditary thrombocytopenia, or pseudothrombocytopenia (clumping on peripheral blood smear)
- Conditions that could alter protein catabolism and/or immunoglobulin G (IgG) utilization (e.g. protein-losing enteropathies, nephrotic syndrome)
- Congestive heart failure (New York Heart Association Stage III or IV)
- Diabetes mellitus
- Paraproteinemia
- Concomitant nephrotoxic drugs
- Hemoglobin level more than 2g/L below the lower limit of normal.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group 1
Infusion #1 (Week 0) IGIV-C (0.08 mL/kg/min); Infusion #2 (Week <6) IGIV-C (0.14 mL/kg/min)
|
IGIV-C 10% at a dose of 1.0g/kg was to be given on 2 occasions as a single daily infusion: Group 1 were to receive their first IGIV-C, 10-% infusion at a rate of 0.08 mL/kg/min and a second infusion at 0.14 mL/kg/min.
and Group 2 were to receive their first IGIV-C, 10-% infusion at a rate of 0.14 mL/kg/min and a second infusion at a rate of 0.08 mL/kg/min.
Other Names:
|
Experimental: Group 2
Infusion #1 (Week 0) IGIV-C (0.14 mL/kg/min); Infusion #2 (Week <6) IGIV-C (0.08 mL/kg/min)
|
IGIV-C 10% at a dose of 1.0g/kg was to be given on 2 occasions as a single daily infusion: Group 1 were to receive their first IGIV-C, 10-% infusion at a rate of 0.08 mL/kg/min and a second infusion at 0.14 mL/kg/min.
and Group 2 were to receive their first IGIV-C, 10-% infusion at a rate of 0.14 mL/kg/min and a second infusion at a rate of 0.08 mL/kg/min.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Free Hemoglobin
Time Frame: 24 hours after treatment
|
Free hemoglobin as a measure to assess hemolysis.
|
24 hours after treatment
|
Hematocrit
Time Frame: 24 hrs after treatment
|
Hematocrit as a measure to assess hemolysis
|
24 hrs after treatment
|
Red Blood Cells
Time Frame: 24 hrs after treatment
|
Red blood cells as a measure to assess hemolysis
|
24 hrs after treatment
|
Change From Baseline in Platelet Levels
Time Frame: 24 hours Post infusion and Day 7
|
24 hours Post infusion and Day 7
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of Subjects With Infusion Related Adverse Events
Time Frame: 48 hours after treatment
|
48 hours after treatment
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: James Bussel, MD, New York Presbyterian Hospital-Weill Medical College of Cornell University
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Immune System Diseases
- Autoimmune Diseases
- Hematologic Diseases
- Hemorrhage
- Hemorrhagic Disorders
- Blood Coagulation Disorders
- Skin Manifestations
- Thrombocytopenia
- Blood Platelet Disorders
- Thrombotic Microangiopathies
- Purpura
- Purpura, Thrombocytopenic
- Purpura, Thrombocytopenic, Idiopathic
- Physiological Effects of Drugs
- Immunologic Factors
- Antibodies
- Immunoglobulins
- Immunoglobulins, Intravenous
- gamma-Globulins
- Rho(D) Immune Globulin
- Immunoglobulin G
Other Study ID Numbers
- 100422
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Purpura, Thrombocytopenic, Idiopathic
-
Protalex, Inc.TerminatedPhase I Safety and Tolerability Study of Staphylococcal Protein A in Adult Patients With Chronic ITPIdiopathic Thrombocytopenic Purpura (ITP)Australia, New Zealand
-
CSL LimitedCompletedIdiopathic Thrombocytopenic Purpura (ITP)Australia
-
University Hospital, BordeauxCompletedChronic Idiopathic Thrombocytopenic Purpura | Congenital Thrombocytopenia
-
University Hospital, AngersMinistry of Health, FranceUnknownAcute Idiopathic Thrombocytopenic PurpuraFrance
-
AmgenCompletedThrombocytopenia | Immune Thrombocytopenia | Idiopathic Thrombocytopenic Purpura | Thrombocytopenia in Pediatric Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) | Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) | Thrombocytopenic PurpuraUnited States, Canada, Australia
-
Neufeld, Ellis J, MD, PhDGenentech, Inc.; Biogen; Glaser Pediatric Research Network; Terrana ITP Research...CompletedImmune Thrombocytopenic Purpura (ITP) | Idiopathic Thrombocytopenic Purpura (ITP)United States
-
Weill Medical College of Cornell UniversityGenentech, Inc.WithdrawnIdiopathic Thrombocytopenic Purpura (ITP)United States
-
Jiangsu HengRui Medicine Co., Ltd.UnknownChronic Idiopathic Thrombocytopenic PurpuraChina
-
GlaxoSmithKlineCompletedChronic Idiopathic Thrombocytopenic Purpura | Purpura, Thrombocytopenic, IdiopathicJapan
-
AmgenCompletedIdiopathic Thrombocytopenic Purpura | Thrombocytopenia in Pediatric Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) | Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
Clinical Trials on Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified
-
Grifols Therapeutics LLCCompleted
-
Grifols Therapeutics LLCCompletedPrimary ImmunodeficiencyUnited States, Canada
-
Grifols Therapeutics LLCCompleted
-
Beth Israel Deaconess Medical CenterGrifols Biologicals, LLCTerminatedDiabetes Mellitus | Diabetes Complications | Diabetic NeuropathiesUnited States
-
Grifols Therapeutics LLCCompletedCommon Variable Immunodeficiency | Severe Combined Immunodeficiency | Wiskott-Aldrich Syndrome | Agammaglobulinemia | Immunologic Deficiency SyndromeCanada, United States
-
Grifols Therapeutics LLCCompletedPrimary ImmunodeficiencySpain, France, Germany, United Kingdom, Australia, Czechia, Hungary, Poland, Sweden
-
Grifols Therapeutics LLCCompletedMacular DegenerationGermany
-
Grifols Therapeutics LLCCompletedMultiple Sclerosis, Relapsing-RemittingCanada, Israel, United States, Austria, Czech Republic, Germany, Greece, Hungary, Poland, Slovakia, Sweden, United Kingdom
-
Grifols Therapeutics LLCCompletedPolyradiculoneuropathy, Chronic Inflammatory DemyelinatingUnited States, Israel, Germany, Czech Republic, Mexico, Argentina, Canada, Italy, Poland, Serbia
-
Baxalta now part of ShireCompletedPrimary Immunodeficiency Diseases (PID)United States